| Literature DB >> 34070593 |
Mark Gray1, Jamie R K Marland2, Alan F Murray3, David J Argyle1, Mark A Potter4.
Abstract
Development of an anastomotic leak (AL) following intestinal surgery for the treatment of colorectal cancers is a life-threatening complication. Failure of the anastomosis to heal correctly can lead to contamination of the abdomen with intestinal contents and the development of peritonitis. The additional care that these patients require is associated with longer hospitalisation stays and increased economic costs. Patients also have higher morbidity and mortality rates and poorer oncological prognosis. Unfortunately, current practices for AL diagnosis are non-specific, which may delay diagnosis and have a negative impact on patient outcome. To overcome these issues, research is continuing to identify AL diagnostic or predictive biomarkers. In this review, we highlight promising candidate biomarkers including ischaemic metabolites, inflammatory markers and bacteria. Although research has focused on the use of blood or peritoneal fluid samples, we describe the use of implantable medical devices that have been designed to measure biomarkers in peri-anastomotic tissue. Biomarkers that can be used in conjunction with clinical status, routine haematological and biochemical analysis and imaging have the potential to help to deliver a precision medicine package that could significantly enhance a patient's post-operative care and improve outcomes. Although no AL biomarker has yet been validated in large-scale clinical trials, there is confidence that personalised medicine, through biomarker analysis, could be realised for colorectal cancer intestinal resection and anastomosis patients in the years to come.Entities:
Keywords: anastomotic leak; biomarkers; colorectal cancer; intestinal anastomosis; precision medicine
Year: 2021 PMID: 34070593 PMCID: PMC8229046 DOI: 10.3390/jpm11060471
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Risk factors associated with the development of an anastomotic leak.
| Patient Factors | Surgical Factors | ||
|---|---|---|---|
| Age | Cardiovascular disease | Poor anastomotic blood supply | Intra-operative sepsis |
Peri-operative techniques for AL risk prediction and diagnosis.
| Pre-Operative | Intra-Operative | Post-Operative |
|---|---|---|
| Surgical factors | Tissue appearance | Scoring systems |
Figure 1Patient samples used for biomarker assessment following a colorectal anastomosis in the treatment of colon cancer. (IL; interleukin, CRP; C-reactive protein, PCT; procalcitonin, WBCC; white blood cell count, I-FABP; intestinal fatty acid binding protein, MMP; matrix metalloproteinases, TIMP; tissue inhibitor of metalloproteinases, VEGF; vascular endothelial growth factor, EGF; epidermal growth factor, PDGF; platelet-derived growth factor, LPS; lipopolysaccharide). Figure created in Biorender.
Figure 2Future applications of advanced technologies for measuring anastomotic leak biomarkers. Implantable sensors placed intra-operatively around the anastomotic site could be left in situ throughout the post-operative recovery period. This concept would allow clinicians to continuously monitor peri-anastomotic biomarkers such as O2, pH, C-reactive protein, lactate and pyruvate levels. This type of continuous monitoring system would help to identify patients at risk of developing an AL due to poor or deteriorating peri-anastomotic intestinal ptO2. It would also allow clinicians the ability to assess the efficacy of interventions designed to improve intestinal ptO2 and prevent a leak from occurring. Figure created in Biorender.